이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Preeclampsia Screening Trial to Improve Outcomes (PRESTO)

2026년 11월 10일 업데이트: Suchitra Chandrasekaran, Emory University

Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy

The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.

The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.

Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.

Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.

연구 유형

중재적

등록 (추정된)

1000

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Georgia
      • Decatur, Georgia, 미국, 30033
        • Emory Decatur Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Pregnant persons aged 18 years or older.
  • Singleton pregnancy.
  • Gestational age from 23 weeks 0 days through 33 weeks 6 days.
  • Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
  • Provision of signed informed consent (English- or Spanish-speaking).

Exclusion Criteria:

  • Enrollment in another therapeutic interventional trial with a primary outcome of HDP
  • Receipt of intravenous heparin during hospitalization.
  • Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
  • Prior study enrollment during the current pregnancy.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Blinded Test Results (Phase A)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units.

Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care.

Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

다른 이름들:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara
실험적: Real Time Results (Phase B)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study.

During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

다른 이름들:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara

sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pregnancy latency
기간: At delivery (up to 40 weeks of gestation)

Time from admission to delivery

At delivery (up to 40 weeks of gestation)
Participants with maternal adverse outcomes
기간: From enrollment until post-natal discharge (on average 10 days post-delivery)

The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive.

From enrollment until post-natal discharge (on average 10 days post-delivery)

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants who require hospital admission
기간: From enrollment up to 37 weeks of gestation

Number of participants who require hospital admission during study participation, collected form medical records.

From enrollment up to 37 weeks of gestation
Number of participants with indicated delivery within 14 days of presentation
기간: Up to 14 days from enrollment

Participants who require delivery within 14 days of presentation

Up to 14 days from enrollment
Number of participants who require transfer to tertiary care centers
기간: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)

Participants who require transfer to tertiary care centers as documented in the medical records.

From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
Number of participants who received antenatal corticosteroid administration
기간: Between 24 weeks and 34 weeks of gestation

Participants who receive antenatal corticosteroid administration as documented in the medical records.

Between 24 weeks and 34 weeks of gestation
Number of preterm births less than 37 weeks
기간: From enrollment up to 36 weeks and 6 days of pregnancy

Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods.

From enrollment up to 36 weeks and 6 days of pregnancy
Number of early preterm births
기간: From enrollment up to 31 weeks and 6 days of pregnancy

Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation.

From enrollment up to 31 weeks and 6 days of pregnancy
Composite Adverse Fetal/Neonatal Outcomes
기간: From maternal enrollment through 28 days after birth

Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups.

From maternal enrollment through 28 days after birth
Length of hospital admission (mother's) of stay,
기간: From admission until post-natal hospital discharge (on average 10 days post-delivery)

Length of hospital admission, extracted from medical records

From admission until post-natal hospital discharge (on average 10 days post-delivery)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Suchitra Chandrasekaran, MD, Emory University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 10월 14일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2026P000788

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.

The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.

IPD 공유 기간

No specific end date has been established.

IPD 공유 액세스 기준

Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.

IPD 공유 지원 정보 유형

  • 연구_프로토콜

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .